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Abstract
Duchenne muscular dystrophy (DMD) patients, having mutations of the DMD gene, present with a range of neuropsychiatric 
disorders, in addition to the quintessential muscle pathology. The neurobiological basis remains poorly understood because 
the contributions of different DMD gene products (dystrophins) to the different neural networks underlying such symptoms 
are yet to be fully characterised. While full-length dystrophin clusters in inhibitory synapses, with inhibitory neurotransmitter 
receptors, the precise subcellular expression of truncated DMD gene products with excitatory synapses remains unresolved. 
Furthermore, inflammation, involving P2X purinoceptor 7 (P2RX7) accompanies DMD muscle pathology, yet any associa-
tion with brain dystrophins is yet to be established. The aim of this study was to investigate the comparative expression of 
different dystrophins, alongside ionotropic glutamate receptors and P2RX7s, within the cerebellar circuitry known to express 
different dystrophin isoforms. Immunoreactivity for truncated DMD gene products was targeted to Purkinje cell (PC) distal 
dendrites adjacent to, or overlapping with, signal for GluA1, GluA4, GluN2A, and GluD2 receptor subunits. P2X7R immu-
noreactivity was located in Bergmann glia profiles adjacent to PC-dystrophin immunoreactivity. Ablation of all DMD gene 
products coincided with decreased mRNA expression for Gria2, Gria3, and Grin2a and increased GluD2 immunoreactivity. 
Finally, dystrophin-null mice showed decreased brain mRNA expression of P2rx7 and several inflammatory mediators. The 
data suggest that PCs target different dystrophin isoforms to molecularly and functionally distinct populations of synapses. 
In contrast to muscle, dystrophinopathy in brain leads to the dampening of the local immune system.
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Introduction
Duchenne muscular dystrophy (DMD), a neuromuscular 
disorder caused by the absence of the dystrophin-encoding 
DMD gene, is frequently associated with a broad range of 
symptoms of brain origin. One third of DMD patients pre-
sent with a cognitive deficit but, and patients collectively 
have reduced IQ scores lower by about 1 SD compared to 
the general population (Cotton et al. 2001; Snow et al. 2013). 
Apart from intellectual deficits, patients also present with a 
variety of neuropsychiatric disorders. These include affec-
tive disorders, autism spectrum disorder, attention deficit 
hyperactivity disorder, obsessive–compulsive disorder, and 
epilepsy (Banihani,  2015; Caspers Conway,  2015; Filippo 
et al. 2012; Hendriksen and Vles 2008; Lee et al. 2018; Par-
isi et al. 2018; Ricotti,  2016). Unfortunately, while these 
abnormalities significantly exacerbate the disease burden, 
relatively little progress has been achieved in understanding 
the neurobiological basis for the neuropsychiatric compo-
nent of DMD.
The key difficulty arises from the very complex expres-
sion pattern of dystrophins in the brain due to extensive 
alternative promoter usage and alternative splicing, result-
ing in variants of both the full-length 427 kDa dystrophin 
(Dp427) and truncated DMD gene products being expressed 
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in different cells of the nervous system (Byers et al. 1993; 
D’Souza et al. 1995; Doorenweerd,  2017; Gorecki et al. 
1992; Lederfein,  1992; Lidov et  al. 1995; Naidoo and 
Anthony 2020; Tinsley et al. 1993). Importantly, dystro-
phins provide a scaffold for a set of cytoplasmic, membrane-
bound, and extracellular proteins, collectively termed the 
dystrophin-associated protein complex (DAPC) (Waite et al. 
2012), which further anchors proteins including receptors 
and ion channels. These protein interactomes vary depending 
on the cellular location and the DMD gene product involved 
(Gawor and Proszynski 2018; Leyva-Leyva et al. 2018), fur-
ther increasing the complexity. While it has long been estab-
lished that a significant proportion of brain dystrophin is 
expressed in postsynaptic compartments (Lidov et al. 1990), 
identification of individual gene products within functionally 
specific populations of synapses remains incomplete. The 
brain expression of Dp427 revealed a complex regional and 
cell type-specific expression profile (Gorecki et al. 1992; 
Huard and Tremblay 1992; Lidov et al. 1990; Sekiguchi 
2009). At a subcellular level, Dp427 has been shown to be 
concentrated in inhibitory synapses and involved in the syn-
aptic anchoring of GABA-A receptors  (GABAARs) (Brunig 
et al. 2002; Knuesel et al. 1999; Krasowska et al. 2014). 
In contrast, the precise distribution and interactome of the 
truncated 71 kDa gene product (Dp71) is yet to be fully 
understood, despite being considered the main dystrophin 
expressed within the mouse brain (Naidoo and Anthony 
2020; Tadayoni et al. 2012). However, convergent molecu-
lar, structural, and electrophysiological analyses suggest its 
enrichment in glutamatergic synapses (Daoud,  2008; Vail-
lend et al. 1999). In addition, the selective deletion of mouse 
Dp71, but not other DMD gene products, results in altered 
hippocampal glutamatergic synapses (Miranda et al. 2011; 
Miranda,  2009) and impaired cerebellum-mediated cogni-
tive performance consistent with abnormalities of pathways 
considered crucial for cerebellar development and function 
(Helleringer,  2018).
Importantly, in addition to neurons, dystrophin is also 
expressed in glia with dystrophic astrocytes displaying 
impairments in glutamate clearance, which can initiate 
neuronal development defects (Patel 2019). In addition, the 
loss of dystrophin and DAPC from glial end-feet is asso-
ciated with a leaky blood–brain barrier (BBB) (Lien et al. 
2012; Nico 2003). This intrinsic BBB permeability could 
be further exacerbated by chronic inflammation (Morris 
et al. 2018), which is a key component of DMD muscle 
pathology (De Pasquale et al. 2012; Nitahara-Kasahara et al. 
2016; Porter,  2003). Yet, changes in the basal immune sta-
tus of the dystrophic brain are poorly understood (Rae and 
O’Malley 2016a). A potential common link between dystro-
phin, cognitive performance, and the immune system is the 
P2X7 purinoceptor (P2RX7). Indeed, P2RX7s are one of 
the main drivers of muscle inflammation in DMD (Young, 
2015) and have also been shown to mediate inflammatory 
processes within the nervous system (Browne 2013). Fur-
thermore, the ablation of P2RX7s in Dp427 dystrophic mice 
alters hippocampal and cortical functions such as improved 
recognition memory and diminished anxiogenic-like behav-
iour (Sinadinos,  2015). However, an association between 
P2RX7s, truncated dystrophin gene products, glutamatergic 
synaptic pathways, and cerebellar function remains to be 
identified. Therefore, the aim of this study was to inves-
tigate the comparative expression of truncated dystrophin 
isoforms, alongside P2RX7s and associated inflammatory 
mediators, using dystrophin gene-deleted mice and dystro-
phin epitope-specific antibodies. We focused on the cerebel-
lum because of its known contribution to cognitive processes 
(Schmahmann and Caplan 2006) and impairments in cer-
ebellar development and function are considered central 
to the DMD brain phenotype (Cyrulnik et al. 2008; Vicari, 
2018). Furthermore, Purkinje cells (PC), the major cerebel-
lar output neurons, also express a PC-specific dystrophin iso-
form, Dp427p (Gorecki et al. 1992). Finally, both inhibitory 
and excitatory abnormalities, as a result of dystrophinopathy, 
have been identified in this brain region (Helleringer et al. 
2018; Knuesel et al. 1999).
Materials and Methods
Animals
The following transgenic mouse models were used in the 
study:
1) The C57 BL/10ScSn-Dmdmdx/J mouse model (Bulfield 
et al. 1984), referred to here as mdx, lacks the full-length 
dystrophin isoforms. These mice were bred on a C57 BL/10 
background.
2) The C57 BL/6-DmdGt(ROSAbgeo)1Mpd/J mouse model 
(Wertz and Fuchtbauer 1998), referred to here as  mdxβgeo, 
has the reading-frame disruption downstream of exon 63, 
one that is present in all dystrophins and, therefore, with all 
isoforms being ablated. Ablation of dystrophin transcripts 
and protein in this model was fully detailed in (Wertz and 
Fuchtbauer 1998; Young  2020). These mice breed normally 
and exhibit no differences in fertility, compared to WT coun-
terparts (Wertz and Fuchtbauer 1998) and our experience. 
These mice were bred on a C57 BL/6 J background.
3) The eGFP-GFAP mouse model which expresses 
enhanced green fluorescent protein (eGFP) under the control 
of the glial fibrillary acidic protein (GFAP) promotor, bred 
on a FVB/N genetic background (Nolte,  2001), was used to 
visualise the cytoplasmic compartment of astrocytes in the 
cerebellum. These mice were kindly provided by Professor 
Arthur Butt at University of Portsmouth.
Cellular and Molecular Neurobiology 
1 3
4) The P2rx7-deficient mouse model is a global knock-
out for the P2RX7 (Solle 2001), bred on a C57 BL/6  J 
background.
Wild-type control mice were, in each instance, of the 
same genetic background as their gene-deleted counterparts.
Adult male mice, aged 2–3 months (coinciding with the 
active dystrophic process in mice) were used throughout this 
project. All mice were maintained in-house by University of 
Portsmouth’s Bioresources Centre, under specific pathogen-
free conditions and in a controlled environment (12-h light/
dark cycle, 19 °C to 23 °C ambient temperature, and 45% to 
65% humidity) with free access to standard chow and water.
Immunohistochemistry
Animal tissue was fixed by inducing anaesthesia with iso-
flurane and maintained with pentobarbitone (1.25 mg/kg of 
bodyweight, IP) and transcardially perfused with 0.9% saline 
solution for 2 min, followed by 10 min of a fixative consist-
ing of 1% formaldehyde and 15% v/v saturated picric acid 
in 0.1 M phosphate buffer (PB), pH 7.4. The relatively weak 
fixation (1%) was deliberately chosen because the majority 
of the targeted epitopes were on integral membrane proteins. 
Since the relevant epitopes of such proteins may be masked 
by formaldehyde cross-linking, this can be minimised by 
using a lower concentration of fixative solution compared 
to the standard 4% formaldehyde protocol (Eyre et al. 2012; 
Lorincz and Nusser 2008). This is particularly applicable to 
glutamate receptors (Watanabe et al. 1998). After the perfu-
sion, the brains were dissected from the skull and post-fixed 
over night at room temperature in the same fixative solution. 
The following day, the brains were rinsed in 0.1 M PB, after 
which 60 μm sagittal sections were prepared using a VT 
1000 vibrating microtome (Leica, Wetzlar, Germany). The 
sections were thoroughly washed in 0.1 M PB to remove 
any residual fixative and then stored in a solution contain-
ing 0.1 M PB and 0.05% w/v sodium azide until further 
processing.
A proteolytic antigen retrieval method was used accord-
ing to (Watanabe et al. 1998) as follows: tissue sections were 
incubated for 10 min at 37 ºC in 0.1 M PB on a shaking 
incubator. The PB was removed and replaced with a solution 
containing 1 mg/ml pepsin (Sigma Aldrich, St Louis, MI, 
USA) dissolved in 0.2 M HCL for 10 min. Subsequently, 
sections were washed three times for 10 min in 50 mM 
TRIS-buffered saline solution containing 0.3% w/v Triton-
X-100 (TBS-Tx). To minimise the non-specific binding of 
secondary antibodies, tissue sections were pre-incubated in 
a TBS-Tx solution containing 20% normal serum from the 
species that the secondary antibodies were raised in (Vector 
Laboratories, Burlingame, CA, USA) for 2 h at room tem-
perature on a horizontal shaker.
Tissue sections were incubated with a cocktail of pri-
mary antibodies diluted in TBS-Tx at 4 ºC overnight on a 
horizontal shaker. Details of the primary antibodies used 
are provided in Supplementary Information (SI) Table 1. 
On the following day, tissue sections were washed in TBS-
Tx three times for 10 min periods to remove unbound anti-
bodies. Tissue sections were then incubated in a cocktail 
containing appropriate secondary antibodies targeted at the 
Fc region of primary antibodies, for 2 h at room tempera-
ture on a horizontal shaker. Secondary antibodies were all 
raised in donkey and conjugated to either Alexa Fluor™ 488 
(Invitrogen, Eugene, OR, USA), indocarbocyanine  (CyTM3) 
or DyLight™ 549, or DyLight™ 649 (Jackson Immunore-
search, West Grove, PA, USA), for 2 h. Sections were then 
washed three times for 10-min periods in TBS-Tx to remove 
unbound antibodies, mounted on glass microscope slides, air 
dried, and sealed with glass coverslips using Vectashield™ 
antifade mounting medium (Vector Laboratories).
Antibody Specificity
The specificity of all antibodies used in this study has been 
fully characterised, as detailed in SI Table 1. Method speci-
ficity was confirmed by omitting primary antibodies in the 
reaction sequence, which served to confirm the specificity 
of secondary antibodies. In the case of double and triple 
immunolabelling experiments, confirmation of the lack of 
cross-reactivity by secondary antibodies was tested by react-
ing a single primary antibody with the full complement of 
secondary antibodies.
Microscopy
Tissue samples were examined with a confocal laser-scan-
ning microscope (LSM 880 with AiryScan or LSM 710; 
Zeiss, Oberkochen, Germany) using a Plan Apochromat 
20x (NA 0.8; pixel size 0.42 μm) objective, Plan Apochro-
mat 40 × DIC oil objective (NA 1.3; pixel size 0.29 μm), 
Plan Apochromat 63 × DIC oil objective (NA 1.4; pixel size 
0.13 μm) objective, or a Plan Apochromat 100 × DIC oil 
objective (NA 1.46; pixel size 0.08 μm). Detection was with 
either PMT or AiryScan detectors. All images presented rep-
resent a single optical section. Images were acquired using 
sequential acquisition of the different channels to avoid 
cross-talk between fluorophores. Pinholes were adjusted to 
1.0 Airy unit. In all cases where multiple images were cap-
tured from the same immunohistochemical reaction, laser 
power, pinhole, and exposure settings were captured once on 
tissue from a representative control section and maintained 
throughout imaging. Images were processed with Zen soft-
ware (Zeiss) and exported into bitmap images for processing 
in ImageJ and Adobe Photoshop (Adobe Systems, San Jose, 
CA, USA). Only brightness and contrast were adjusted for 
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the whole frame, and no part of any frame was enhanced or 
modified in any way.
Colocalisation Analyses
The degree of overlap between immunoreactivity for dys-
trophin-CT, P2RX7, and a range of molecular markers was 
assessed, according to previously published protocols (Kelly, 
2020). Imaging and quantification were performed as fol-
lows: using a Plan Apochromatic 100 × DIC oil objective: 
within three tissue sections per animal (n = 5 WT mice), 
five fields of view were imaged within lobules one, five and 
10, in order represent signal throughout the anterior–poste-
rior extent of the cerebellum. Z-stacks consisting of three 
optical sections were acquired for each field of view. The 
optical sections were spaced 15 µm apart in the Z-plane 
in order to prevent overlap of signal across optical sec-
tions or individual neurons. The dimensions of each opti-
cal section were 42.7 µm × 42.7 µm × 0.7 µm in the X–Y-Z 
planes. The Coloc2 function in ImageJ was then used to 
quantify the relative degree of co-occurrence of overlap-
ping pixels, using the Manders’ overlap coefficient (MOC) 
(Manders et al. 1993), for individual signals. Average values 
were obtained for tissues sections and then individual ani-
mals. The mean ± SEM MOC was computed for N = 5 WT 
mice. These data are presented in the Results section of the 
manuscript.
To approximate the degree of potential random colocali-
sation, the MOC was recomputed using a mirrored view of 
either the dystrophin or P2RX7 images, by changing their 
orientation in the horizontal plane. This mirrored MOC 
was then expressed as a percentage of the original MOC to 
indicate the potential level of random colocalisation. These 
mirror image data, alongside all MOC data, are tabulated 
in SI Table 2.
Semi‑quantitative Analysis of Changes 
in Ionotropic Glutamate Receptors (iGluR) 
Subunit Immunoreactivity Between WT 
and Dystrophin‑deficient mice
The purpose of the quantitative cluster analysis was to deter-
mine relative changes in the density and area of clusters 
immunoreactive for specific glutamate receptor subunits 
between mdx,  mdxβgeo and their WT counterparts. Immuno-
histochemical protocols for each individual glutamate recep-
tor subunit were optimised to ensure optimal signal-to-noise 
separation. Acquisition parameters for an individual subunit 
were optimised within the initial field of view. These settings 
were then identically applied across all fields of view and all 
tissue sections from WT and dystrophin-deficient mice. A 
Plan Apochromatic 100 × DIC oil immersion objective was 
used. Each image represents one optical section of 28.31 
µm2 in the X–Y plane with the Z-plane adjusted for 1.0 Airy 
unit. Five fields of view were captured for each imaged lob-
ule per animal. These settings were chosen to enable consist-
ent imaging of immunoreactive puncta-enriching dendritic 
spines. All fields of view were taken with the centre region 
approximately equidistant from the PC layer and pial sur-
face. The ImageJ Cluster Analysis tool (open source, https:// 
fiji. sc/) was used to quantify the number of immunoreac-
tive puncta as follows. A micrograph from a WT sample 
was selected, and an intensity threshold was manually set to 
separate background signal from immunolabelling. These 
setting were applied to all images. The micrograph was then 
converted into a binary image, and a watershed filter was 
applied to separate adjacent but overlapping puncta. Finally, 
puncta were quantitatively characterised using the Particle 
Analysis algorithm.
Quantitative Reverse‑Transcription Polymerase 
Chain Reaction
Animals were killed by cervical dislocation and tissue 
homogenates prepared. To prevent degradation of nucleic 
acid in samples, fresh tissue was dissected and immedi-
ately submerged in liquid nitrogen. Total RNA was isolated 
from the samples using an RNeasy Mini kit (Qiagen, Venlo, 
Netherlands) according to the manufacturer’s protocol. 
Briefly, tissue samples were submerged in a lysis buffer and 
homogenised. Samples were then centrifuged, and super-
natants extracted. The supernatants were then mixed with 
equal volumes of 70% ethanol to prepare RNA for bind-
ing to centrifugation columns. Samples were then added to 
centrifugation columns and washed by centrifugation with 
two wash buffers. Finally, RNA was eluted by addition of 
nuclease-free water and centrifuged. Samples were stored 
at − 80 ºC. The quality and quantity of the extracted RNA 
in each tissue were examined with a NanoDrop™ spectro-
photometer (ThermoFisher Scientific) and then reverse tran-
scribed to provide cDNA templates for PCR and quantitative 
real-time PCR (qRT-PCR) reactions. Reverse-transcription 
was achieved by incubating RNA isolates for 2 h at 37 ºC 
in a cocktail containing: 200 ng RNA in 10% v/v reverse 
transcription buffer (New England Biolabs, Ipswitch, MA, 
USA), 5% of Oligo(dT) primers (ThermoFisher Scientific), 
5% DNTPs (ThermoFisher Scientific), 2.5% M-MulV 
reverse transcriptase (Applied Biosystems, Foster City, CA, 
USA), and 2.5% RiboLock RNase inhibitor (ThermoFisher 
Scientific) made up to 20 µL with nuclease-free water.
qRT-PCR amplification was performed in 96-well plates 
in a cocktail containing a TaqMan®-specific mastermix 
(Roche, Burgess Hill, UK), and TaqMan® probes (see SI 
Table 3) and performed using a LightCycler® 96 system 
(Roche). The cycling conditions were 95 ºC for 600 s, fol-
lowed by 40 cycles of 95 ºC for 15 s and 60 ºC for 60 s. 
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Samples were loaded containing probes for the gene of inter-
est (GOI) and Gapdh, which was used as a reference gene for 
relative mRNA quantification calculations. A standard curve 
comprising serial dilutions of known RNA concentrations 
was prepared alongside every sample set and loaded onto the 
96-well microplate. All samples were loaded in 10 µL dupli-
cates to reduce technical variability. Standard curves were 
graphically analysed for reaction efficiency of each primer as 
well as between gene of interest (GOI) and reference gene, 
and for pipetting consistency. Assays in which the reaction 
efficiency was within 90–120%, and similar between GOI 
and reference genes were analysed. Linear regression of the 
line produced by a graph of  Ct against RNA concentration 
was performed and the relative concentration calculated 
using the following formulae:
where α is the product of the linear regression, e is Eul-
er’s number (2.718281828),  Ct; cycle threshold is the cycle 
number at which the qRT-PCR machine detects fluorescence 
over a pre-defined threshold, m is the gradient of the stand-
ard curve line of best fit, c is the intercept, and x is the calcu-
lated level of GOI mRNA relative to Gapdh mRNA levels in 
the sample. This technique was chosen as it allowed the per-
formance of extra quality control steps and reduce any inter-
experiment variability. qRT-PCR assays were duplicated or 
triplicated using samples from separate cohorts of animals 
and relative mRNA levels pooled for statistical analyses.
Statistical Analysis
In all cases, GraphPad Prism (GraphPad Software, La Jolla, 
CA, USA) was used for statistical analyses and graphical 
presentation of the data. The Shapiro–Wilk test was used 
to determine the normality of data point distribution within 
sample groups. Normally distributed data were tested for 
significance using an unpaired two-tailed Student’s t test. 
Non-normally distributed data were tested for significance 
using the Mann–Whitney U test. An alpha level of < 0.05 
was used to determine statistical significance. For graphical 
presentation of quantitative data, bars represent the means 
and the error bars the SEM.
𝛼 = ê((Ct − m)∕c)
(GOI)∕(Gapdh) = x
Results
Confirmation of the specificity of dystrophin 
antibodies
The main anti-dystrophin antibody used throughout the 
study is directed to an amino acid sequence of the C-ter-
minus of dystrophin (dystrophin-CT), which is common to 
all dystrophin isoforms. Previously published western blot 
data for this antibody indicate that in the cerebellum and 
hippocampus, it recognises the full-length dystrophin, as 
well as the truncated 140 kDa (Dp140) and Dp71 dystro-
phins (Hendriksen,  2016). In this study, the dystrophin-
CT antibody produced strong signal throughout the brain 
of WT mice, with particular enrichment noticeable in the 
olfactory bulb, dentate gyrus, and cerebellum (Fig. 1 A1). 
In mdx mice, which lack Dp427, there was a noticeable 
decrease in the intensity of dystrophin-CT immunoreactiv-
ity, reacted, and imaged under conditions identical to WT 
tissue (Fig. 1 A2). In contrast, no specific dystrophin-CT 
signal was detected in tissue from  mdxβgeo mice, which 
lack all dystrophins (Fig. 1 A3).
Previous reports indicate that Dp427 is expressed at 
inhibitory synapses on PCs, where it anchors  GABAARs 
(Brunig et  al. 2002; Knuesel et  al. 1999). We, there-
fore, first sought to replicate this immunoreactivity pat-
tern using antibodies directed to either the N terminus 
of Dp427 (dystrophin-NT antibody), or the C-terminus, 
using the dystrophin-CT antibody, since it recognises all 
dystrophins in the cerebellum (Hendriksen et al. 2016). 
In tissue from WT mice, dystrophin-NT immunoreactiv-
ity was predictably restricted to the somatic and proximal 
dendritic regions of PCs (Fig. 2 A1), in a manner similar 
to the pattern presented in (Knuesel et al. 1999), and where 
inhibitory synapses are concentrated in this cell type. No 
specific dystrophin-NT signal was detected in tissue from 
mdx mice (Fig. 2 A2) nor  mdxβgeo mice (Fig. 2 A3). This 
suggests that signal from the dystrophin-NT antibody, 
located in inhibitory synaptic domains, corresponds to 
full-length dystrophin.
Immunoreactivity for dystrophin-CT presented as two 
distinct patterns of labelling. Apart from labelling blood 
vessels, signal was localised to not only the somatic 
compartments in a manner similar to the dystrophin-NT 
antibody, but also throughout the molecular layer where 
excitatory synapses predominate (Fig. 2 B1). However, 
in contrast to the dystrophin-NT antibody, while dystro-
phin-CT labelling in mdx mice was ablated in somatic 
and proximal dendritic compartments where inhibitory 
synapses are predominantly located, signal persisted 
in distal dendritic regions of the molecular layer which 
contain excitatory synapses (Fig. 2 B2). Only residual, 
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non-specific dystrophin-CT signal was detectable in tis-
sue from  mdxβgeo mice (Fig. 2 B3). This step-wise loss of 
dystrophin labelling patterns correlating with cumulative 
loss of dystrophins suggests a differential expression of 
isoforms at specific PC subcellular compartments. Fur-
thermore, these data indicate that putative-truncated DMD 
gene products are likely to be preferentially expressed in 
the vicinity of excitatory synapses and blood vessels, in 
line with previous evidence (Daoud et al. 2008; Haenggi 
et al. 2004).
Putative Short Dystrophins are Associated 
with Neurons and Glia in the Molecular Layer 
of the Cerebellar Cortex
Expression of short dystrophins is reportedly associated with 
both neuronal and glial elements in the brain (Daoud et al. 
2008; Haenggi and Fritschy 2006). High-resolution imag-
ing of dystrophin-CT immunoreactivity within the molecu-
lar layer revealed individual clusters (Fig. 3 A1-2) located 
either in the neck or the head of dendritic spines (Fig. 3 A3). 
Since PC dendritic spines are ensheathed by Bergmann glia 
processes, such signal, at this resolution could be representa-
tive of expression within such glial networks. To explore 
this further, we used tissue from mice expressing enhanced 
green fluorescent protein (eGFP) under the control of the 
glial fibrillary acidic protein (GFAP) promotor, which in 
the cerebellum reveals astrocytes, and Bergmann glia, in 
particular. The benefit of such a tool is that the eGFP sig-
nal fills the cytoplasmic compartments of Bergmann glia in 
their entirety, thus, allowing for the visualisation of the full 
extremities of these cells. As expected, eGFP-GFAP signal 
presented as a network of processes contacting PCs around 
their somata and dendrites (Fig. 3 B1). Clusters immunore-
active for dystrophin-CT associated with GFAP-eGFP signal 
was in the form of clusters on Bergmann glia shafts as well 
the periphery of putative blood vessels (Fig. 3 B2-3). A 3D 
volumetric reconstruction of the region in (Fig. 3B), dem-
onstrating the close association between dystrophin-CT and 
glial processes is provided as a SI media file (LINK). This 
suggests that the putative short dystrophins are expressed by 
PCs and glia. In addition, since Bergmann glial processes 
are known to ensheath excitatory synapses on PC spines, this 
further suggests the expression of short dystrophins in the 
close vicinity of glutamatergic synapses.
Putative Full‑Length and Truncated Dystrophins are 
Differentially Localised to Inhibitory and Excitatory 
Synaptic Sites, Respectively
The patterns of labelling corresponding to putative full-
length and truncated dystrophins in Fig. 2 appeared to coin-
cide with the locations of inhibitory and excitatory syn-
apses, respectively. To verify this, we assessed signal for 
the dystrophin-CT antibody alongside molecular markers 
of inhibitory and excitatory synapses, in tissue from WT 
mice. Dystrophin-CT immunoreactive clusters, on somatic 
and proximal dendritic compartments of PCs, were located 
in close association with terminals immunopositive for the 
vesicular GABA transporter (VGAT), a protein expressed 
exclusively in the membranes of synaptic vesicles which 
Fig. 1  Confirmation of the specificity of dystrophin immunoreactiv-
ity and its association with specific subcellular neuronal domains 
and glial cells of the cerebellar cortex. (A1) low power overview of 
dystrophin immunoreactivity with an antibody that is targeted to the 
C-terminus of dystrophin protein (dystrophin-CT) in a sagittal sec-
tion of a wild type (WT) mouse brain. Signal is widespread through-
out the brain, but particularly enriched in the olfactory bulb, dentate 
gyrus, and cerebellum. (A2) dystrophin-CT immunoreactivity in 
tissue from the mdx mouse, which lacks the full-length dystrophin 
isoform (Dp427), reacted, and imaged under conditions identical for 
(A1) samples. Note the significant decrease in the overall intensity 
of the signal. (A3) dystrophin-CT immunoreactivity in tissue from 
the  mdxβgeo mouse, which lacks all dystrophin isoforms, reacted, and 
imaged under conditions identical for (A1) and (A2) samples. Note 
the absence of any detectable specific signal indicating the specificity 
of the antibody. Scale bars 1.5 mm
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contain either GABA or glycine, and is, thus, predictive 
of the release sites for these inhibitory neurotransmitters 
(Fig. 4 A 1–4). Manders’ overlap coefficient (MOC) analysis 
(Manders et al. 1993) was performed to assess the degree of 
colocalised pixels between dystrophin-CT and VGAT, and 
vice versa. This measure quantifies the proportion of co‐
occurrence of overlapping pixels between two signals and 
ranges between 0 and 1. The MOC for dystrophin-CT sig-
nal overlapping with VGAT was 0.10 ± 0.02, N = 5 animals. 
The MOC for VGAT signal overlapping with dystrophin-CT 
was 0.22 ± 0.06 (Fig. 4 A5). This low association with this 
presynaptic markers confirms the predominant postsynaptic 
location of dystrophin.
Since this somatodendritic dystrophin-CT signal was 
ablated in the full-length Dp427-null mouse (mdx) (Fig. 2 
B2), this confirms previous reports that full-length dystro-
phin expression is most likely restricted to inhibitory syn-
apses. However, a proportion of dystrophin-CT immuno-
reactive clusters, presumably representing the expression 
of short isoforms, was also associated with pre- and post-
synaptic markers of excitatory synapses, within PC distal 
dendritic domains. Dystrophin-CT immunoreactive clusters 
Fig. 2  Association of dystrophin 
immunoreactivity with specific 
subcellular neuronal domains 
of the cerebellar cortex. (A1) 
shows immunoreactivity for 
dystrophin with an antibody that 
is targeted to the N terminus 
of Dp427 (dystrophin-NT) in a 
sagittal section of the cerebel-
lum of a WT mouse. Individual 
clusters are concentrated on 
somatic and proximal dendritic 
regions of Purkinje cells (PC), 
identified by immunoreactivity 
for calbindin. No specific dys-
trophin-NT signal was detected 
in samples from (A2) mdx and 
(A3)  mdxβgeo mice. (B1) shows 
dystrophin-CT immunoreactiv-
ity in the molecular layer of a 
WT mouse. Signal is located 
on the somatic and proximal 
dendritic domains of PCs, as 
well as on their distal dendrites, 
in addition to blood vessels. 
(B2) dystrophin-CT immunore-
activity in the cerebellum of an 
mdx mouse shows the ablation 
of signal from PC somatic and 
proximal dendritic regions, 
with signal in dendritic regions 
and blood vessels persisting. 
(B3) no specific dystrophin-CT 
immunoreactivity is detected in 
the cerebellum of  mdxβgeo mice. 
Scale bars 10 µm
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were also located in close proximity to, or partially over-
lapped with, puncta immunopositive for postsynaptic density 
95 (PSD-95), a synaptic scaffold protein that regulates the 
trafficking and localisation of glutamate receptors (Huganir 
and Nicoll 2013) (Fig. 4 B1-4). The MOC for dystrophin-
CT signal overlapping with PSD-95 was 0.37 ± 0.02, N = 5 
animals. The MOC for PSD-95 signal overlapping with dys-
trophin-CT was 0.32 ± 0.01 (Fig. 4 B5). Signal for dystro-
phin-CT was also located either adjacent to, or overlapping 
with immunoreactivity for synapse-associated protein-97 
(SAP97), another postsynaptic scaffolding and trafficking 
protein strongly associated with glutamate receptors (Fig. 4 
C1-4). The MOC for dystrophin-CT signal overlapping with 
SAP97 was 0.34 ± 0.01, N = 5 animals. The MOC for SAP97 
signal overlapping with dystrophin-CT was 0.44 ± 0.01 
(Fig. 4 C5). Further evidence of the association of truncated 
dystrophins with glutamatergic synapses was the location 
of dystrophin-CT immunoreactive clusters in apposition to 
puncta immunoreactive for vesicular glutamate transporter 
1 (VGLUT1) (Fig. 4 D1-4) and vesicular glutamate trans-
porter 2 (VGLUT2) (Fig. 4 E1-4), which are located prefer-
entially within two glutamatergic afferent systems for PCs, 
namely parallel and climbing fibres, respectively. The MOC 
for dystrophin-CT signal overlapping with VGLUT1 was 
0.18 ± 0.01, N = 5 animals, while the MOC for VGLUT1 sig-
nal overlapping with dystrophin-CT was 0.11 ± 0.001 (Fig. 4 
D5). The MOC for dystrophin-CT signal overlapping with 
VGLUT2 was 0.10 ± 0.007, N = 5 animals, while the MOC 
for VGLUT2 signal overlapping with dystrophin-CT was 
0.13 ± 0.005 (Fig. 4 E5). Thus, collectively, a larger of pro-
portion of dystrophin-CT signal was preferentially associ-
ated with post-, rather than presynaptic marker proteins for 
glutamate synapses.
Since this quotient of dystrophin-CT labelling was ablated 
in the dystrophin-null  mdxβgeo mouse model, but present in 
the Dp427-null mdx mouse model (Fig. 2), this suggests 
that short DMD gene products are targeted to glutamatergic 
synapses.
Immunoreactivity for Truncated Dystrophins 
is Located in Close Association with Diverse 
Glutamate Receptor Subtypes
Given the above location of a proportion of dystrophin-CT 
immunoreactive clusters with that of molecular markers of 
glutamatergic synapses, we next explored whether signal 
Fig. 3  (A) high-resolution image of dystrophin-CT immunoreactiv-
ity indicating that the signal is concentrated as individual clusters in 
the necks and heads of PC dendritic spines, identified by calbindin 
immunoreactivity. (A3) is a magnified view of the boxed area in (A1) 
and (A2). (B1) visualisation of Bergmann glia processes in the cer-
ebellum, using green fluorescence protein (GFP) signal, the expres-
sion of which is driven by the promotor for glial fibrillary acid protein 
(GFAP). (B2) in the same field of view, dystrophin-CT immunoreac-
tivity presents as individual clusters as well as profiles reminiscent of 
blood vessels (arrows). (B3) is a magnified view of the boxed areas 
in (B1 and 2) indicating the dystrophin-CT immunoreactive clusters 
located on GFP-GFAP profiles which are likely Bergmann glia shafts 
(arrowheads), as well as lining a putative blood vessel (arrow). Scale 
bars: (A) 2 µm; (B) 5 µm
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for such putative-truncated dystrophin was associated with 
immunoreactivity for AMPA and NMDA receptor subunits. 
An important technical caveat is that the proteolytic antigen 
retrieval method essential for the visualisation of membrane-
bound AMPA and NMDA receptor subunits (Watanabe et al. 
1998) also results in the ablation of cytoplasmic signal, such 
as calbindin immunoreactivity, especially in cellular com-
partments with low levels of such signal such as dendritic 
spines. This can create the impression that AMPA, NMDA, 
and dystrophin signal is adjacent to, but not within PCs, 
potentially in neighbouring glial elements. However, numer-
ous independent studies, using ultrastructural analyses, have 
unequivocally demonstrated the expression of glutamate 
receptors in postsynaptic compartments of PCs (Masugi-
Tokita et al. 2007; Tanaka,  2005; Zhao et al. 1998). A fur-
ther technical clarification is that the co-analysis of AMPA 
subunits with the dystrophin-CT antibody was restricted to 
the GluA1 (Fig. 5 A) and GluA4 (Fig. 5 B) subunits since 
available, validated antibodies for the GluA2 and 3 subunits 
were raised in the same species. Immunoreactivity for both 
GluA1 (Fig. 5 A2) and GluA4 (Fig. 5 B2) was located in 
PCs, in agreement with previous reports. Clusters immu-
noreactive for dystrophin-CT frequently overlapped with or 
were in close apposition to GluA1 (Fig. 5 A3-4) or GluA4 
(Fig. 5 B3-4) immunoreactive clusters. The MOC for dys-
trophin-CT signal overlapping with GluA1 was 0.31 ± 0.01, 
N = 5 animals, while the MOC for GluA1 signal overlap-
ping with dystrophin-CT was 0.21 ± 0.01 (Fig. 5 A5). The 
MOC for dystrophin-CT signal overlapping with GluA4 was 
0.31 ± 0.01, N = 5 animals, while the MOC for GluA4 signal 
overlapping with dystrophin-CT was 0.20 ± 0.01 (Fig. 5 B5).
Immunoreactivity for the GluN2A subunit (Fig. 5 C2) 
followed a similar pattern to that of the GluA1 and GluA4 
subunits. However, their association with dystrophin-CT 
immunopositive clusters (Fig. 5 C3-4) appeared less cogent, 
compared to their AMPA receptor counterparts, with only 
a minority of overlap being evident, which was borne out 
by the colocalisation analyses. The MOC for dystrophin-
CT signal overlapping with GluN2A was 0.15 ± 0.01, N = 5 
animals, while the MOC for GluN2A signal overlapping 
with dystrophin-CT was 0.12 ± 0.01 (Fig. 5 C5). This could 
be because GluN2A is reportedly located on neighbouring 
interneurons and not considered to be expressed by PCs 
themselves (Bidoret et al. 2015). In contrast to all other 
subunits investigated, immunoreactivity for GluD2 showed 
the strongest association with signal for dystrophin-CT, with 
the majority of clusters located in close association, or over-
lapping with dystrophin (Fig. 5 D1-4). This was confirmed 
by the colocalisation analyses. The MOC for dystrophin-
CT signal overlapping with GluD2 was 0.66 ± 0.01, N = 5 
animals, while the MOC for GluD2 signal overlapping with 
dystrophin-CT was 0.37 ± 0.01 (Fig. 5 D5). Collectively, 
these data suggest that specific glutamate receptor subtypes, 
GluD2 in particular, could being part of, or directly associ-
ated with the DAPC in the cerebellum, and their expression 
and function could be altered in dystrophinopathy.
Specific iGluR Subunit Expression is Altered 
by the Total Dystrophin Absence, but not Dp427 
Loss
Since we observed immunoreactive puncta for putative-
truncated dystrophins in close association with excitatory 
synapses in the cerebellar molecular layer, we, therefore, 
assessed whether the expression of the predominant iGluR 
transcripts was altered in the absence of dystrophin. This 
analysis was undertaken at the RNA and protein levels in 
mdx and  mdxβgeo cerebellar samples, to compare the full-
length vs. total dystrophin absence, respectively. In samples 
from  mdxβgeo mice, qRT-PCR analyses revealed that the rel-
ative mRNA levels for the Gria2 (P = 0.0181 unpaired Stu-
dent’s t test, N = 12 animals), Gria3 (P = 0.0034, unpaired 
Student’s t test, N = 12 animals), Grin2a (P = 0.0014, 
U = 14, Mann–Whitney U test, N = 12 animals), and Grin2b 
(P = 0.0426, unpaired Mann–Whitney U test, N = 12 ani-
mals) were significantly decreased compared to wild type 
controls (Fig. 6 A). However, the Gria1, Gria4, Grin1, and 
Grid2 transcripts in  mdxβgeo cerebella were not statistically 
significantly altered (SI Table 4). Importantly, we detected 
no significant differences in the iGluR mRNA expression 
levels in mdx mice (SI Table 4), further supporting an asso-
ciation of the short-form dystrophins with excitatory syn-
apses. In order to examine whether these dystrophin-related 
alterations in iGluR subunits were specific to the cerebel-
lum, we also examined the mRNA expression of AMPA and 
NMDA receptor subunits within the hippocampus, a brain 
region enriched with iGluRs. We detected no significant dif-
ferences in the iGluR mRNA expression levels in  mdxβgeo 
hippocampi, compared to the WT mice (SI Table 5).
Since the expression of transcripts encoding select 
AMPA and NMDA subunits was altered in  mdxβgeo mice, 
we then examined whether this manifested at the protein 
level, as a change in the distribution or amount of receptor 
proteins. In order to control for the rostro-caudal distri-
bution of cerebellar circuits, three regions were targeted: 
the anterior, posterior, and flocculonodular lobes of the 
cerebellar vermis. Semi-quantitative analysis of GluD2 
immunoreactivity revealed a significant increase in both 
the density (Posterior lobe, p = 0.0236; flocculonodular 
lobe, p = 0.006, unpaired Student’s t test; n = 5 animals), 
and size of clusters (Posterior lobe, p = 0.0423; Flocculo-
nodular lobe, p = 0.0271, unpaired Student’s t test; N = 5 
animals) (Fig. 6 B). However, there were no statistically 
significant changes in immunoreactivity for the GluA1–4 
and GluD1 subunits (SI Table 6). Collectively, these data 
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demonstrate that loss of truncated dystrophins within the 
cerebellum causes transcriptional downregulation of spe-
cific iGluRs, which is mostly compensated at the protein 
level but, unexpectedly, accompanied by significantly 
greater GluD2 clusters, which showed the strongest asso-
ciation with dystrophin-CT.
Putative Truncated Dystrophins are Located 
Adjacent to Glial P2RX7s in the Cerebellum
Ablation of P2RX7 not only alleviated muscle pathology but 
also results in improvements in cortex-mediated object rec-
ognition memory and in reduced anxiety-like behaviour in 
mdx (Dp427-null) mice (Sinadinos et al. 2015). These data 
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indicate the important role of P2RX7 in the dystrophic brain, 
but whether this is linked to inflammation (Gorecki 2019; Rae 
and O’Malley 2016b), or cooperation with GABA and glu-
tamate receptors (Papp et al. 2004) is unknown. Therefore, 
we explored whether P2RX7s are localised in proximity to 
dystrophin. Immunoreactivity for P2RX7 was enriched in the 
molecular layer of the cerebellum, with lower levels of stain-
ing evident in the granular cell layer (Fig. 7A), in agreement 
with previous studies (Atkinson et al. 2004). The specificity 
of the P2RX7 antibody staining was confirmed in samples 
from P2RX7 knockout mice, in which no specific signal was 
detected (Fig. 7B). Previous reports indicate the P2RX7 in the 
cerebellum to be located in Bergmann glia (Habbas et al. 2011; 
Kaczmarek-Hajek 2018). We confirmed this in tissue from 
eGFP-GFAP mice, with P2RX7 immunoreactive clusters over-
lapping with eGFP-containing processes within the molecular 
layer, which represents Bergman glia profiles (Fig. 7 C1-4). 
The MOC for P2RX7 signal overlapping with GFP-GFAP was 
0.49 ± 0.01, N = 5 animals, while the MOC for GFP-GFAP 
signal overlapping with P2RX7 was 0.83 ± 0.01 (Fig. 7 C5), 
confirming previous reports of the significant association of 
P2RX7 expression with glial elements.
The pattern of P2RX7 immunoreactivity closely resem-
bled that of dystrophin in the cerebellum. We, therefore, 
explored whether there was any association between these 
molecules. Within the molecular layer, clusters immunore-
active for dystrophin-CT were in close apposition to those 
immunopositive for P2RX7, putatively on Bergmann glia 
processes (Fig. 7 D1-4). The MOC for P2RX7 signal over-
lapping with dystrophin-CT was 0.31 ± 0.01, N = 5 animals, 
while the MOC for dystrophin-CT signal overlapping with 
P2RX7 was 0.39 ± 0.01 (Fig. 7 D5). Since Bergman glia 
processes closely contact PC spines and excitatory synapses, 
we next explored whether P2RX7 immunolabelling could 
be associated with signal for iGluRs, in a manner similar 
to dystrophin. The respective immunoreactivity patterns 
for P2RX7 and GluA1 closely mirrored one another (Fig. 7 
E1-4), with individual clusters either overlapping or being 
located in close apposition. The MOC for P2RX7 signal 
overlapping with GluA1 was 0.41 ± 0.01, N = 5 animals, 
while the MOC for GluA1 signal overlapping with P2RX7 
was 0.49 ± 0.01 (Fig. 7E5). This suggests that P2RX7 is 
expressed in Bergmann glia profiles which are most likely 
adjacent to glutamatergic synapses. No association was 
observed between P2RX7 and dystrophin on somatic and 
proximal dendritic compartments corresponding to Dp427, 
suggesting that it is specifically associated with isoforms 
located in glutamatergic synapses, but not inhibitory syn-
apses on PCs. Furthermore, P2RX7 located at PC synapses 
could have implications for neuronal signalling in the dys-
trophic brain. Indeed, electrophysiological evidence has 
shown that P2RX7 modulates presynaptic release of gluta-
mate by neurons (Atkinson et al. 2004; Ireland et al. 2004; 
Leon et al. 2008) and astrocytes (Duan et al. 2003). Thus, 
the co-location of P2RX7 and truncated dystrophins in 
excitatory synaptic domains raises the question whether the 
absence of dystrophin, such as in DMD, impacts on P2RX7 
function and, consequently, its contribution to glutamate-
mediated functions in the brain, which apart from neuro-
transmission, also include neuroinflammation (Volpi et al. 
2012).
Loss of all DMD Gene Products Results in Decreased 
Brain Expression of P2rx7 and Immune Modulators
Previous evidence indicates that the deletion of dystro-
phin results in an increase in muscle P2RX7 expression, 
Fig. 4  Different dystrophin isoforms are targeted to inhibitory and 
excitatory synapses in WT mice. (A1–4) Dystrophin-CT immunore-
active clusters are closely associated with puncta immunoreactive for 
the vesicular GABA transporter (VGAT) (arrowheads), a marker of 
inhibitory axon terminals. Note that this somatic-proximal dendritic 
proportion of dystrophin-CT immunoreactivity was ablated in the 
mdx mouse, which lacks the full- length (Dp427) dystrophin isoform 
(Fig.  2 B2). This suggests that Dp427 is targeted to inhibitory syn-
apses. (A5) quantification of the relative overlap of dystrophin-CT 
signal with VGAT, and VGAT with dystrophin-CT, according to the 
Manders’ overlap coefficient method. The bars represent the means, 
and the errors the SEM. N = 5 animals. (B1–4) dystrophin-CT immu-
noreactivity within the distal molecular layers is located on PC den-
drites adjacent (arrowheads) to, and partially overlaps with, clusters 
immunopositive for postsynaptic density 95 (PSD-95), a protein 
integral for the trafficking of glutamate receptors to excitatory syn-
apses and is, thus, indicative of the postsynaptic locations of such 
receptors and synapses. (B5) quantification of the relative overlap 
of dystrophin-CT signal with PSD-95, and PSD-95 with dystrophin-
CT, according to the Manders’ overlap coefficient method. The bars 
represent the means, and the errors the SEM. N = 5 animals. (C1–4) 
shows that dystrophin-CT immunoreactivity also is located adjacent 
to, or partially overlaps with (arrowheads), clusters immunopositive 
for synapse-associated protein-97 (SAP97), a protein that is integral 
in the trafficking of glutamate receptors to excitatory synapses and 
is, thus, indicative of the postsynaptic locations of such receptors and 
synapses. (C5) quantification of the relative overlap of dystrophin-
CT signal with SAP97, and SAP97 with dystrophin-CT, according 
to the Manders’ overlap coefficient method. The bars represent the 
means, and the errors the SEM. N = 5 animals. (D1–4) Proportion of 
dystrophin-CT immunoreactive clusters is located in close apposi-
tion (arrowheads) to puncta immunoreactive for the vesicular gluta-
mate transporter 1 (VGLUT1), a marker of the presynaptic domains 
of parallel fibres in the cerebellum. (D5) quantification of the rela-
tive overlap of dystrophin-CT signal with VGLUT1 and VGLUT1 
with dystrophin-CT, according to the Manders’ overlap coefficient 
method. The bars represent the means, and the errors the SEM. N = 5 
animals. (E1–4) Proportion of dystrophin-CT immunoreactive clus-
ters is located in close apposition (arrowheads) to puncta immunore-
active for the vesicular glutamate transporter 2 (VGLUT2), a marker 
of the presynaptic domains of climbing fibres in the cerebellum. (E5) 
quantification of the relative overlap of dystrophin-CT signal with 
VGLUT2, and VGLUT2 with dystrophin-CT, according to the Man-
ders’ overlap coefficient method. The bars represent the means, and 
the errors the SEM. N = 5 animals. Scale bars: (A1–3) 5  µm; (A4) 
2 µm; (B) 3 µm; (C1–3) 2 µm; (C4) 1 µm; (D1–3) 2 µm; (D4) 1 µm; 
(E) 2 µm
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which is understood to be instrumental in driving muscle 
pathology (Sinadinos et al. 2015). We, therefore, explored 
whether brain P2RX7 expression is also altered in the 
absence of dystrophin, and whether any changes in basal 
immune function could be detected. We first confirmed 
that, like in mdx, hind-limb tibialis anterior (TA) muscle, 
P2rx7 expression was also significantly increased in TA 
samples from  mdxβgeo mice (P = 0.04; unpaired Student’s 
t test, N = 7 animals) (Fig. 8A). In contrast to muscle, in 
brain samples from these same animals, qRT-PCR revealed 
that P2rx7 expression was significantly decreased in samples 
from the cerebellum (p = 0.0008, unpaired Student’s t test, 
N = 13 animals) (Fig. 8B) and hippocampus (p = 0.0049, 
unpaired Student’s t test, N = 12 animals) (Fig. 8C), but 
not the neocortex (p = 0.1086, unpaired Student’s t test, 
N = 4 animals) (Fig. 8D). In contrast, while we confirmed 
a significant increase in P2rx7 expression in mdx muscle, 
(p = 0.0281, unpaired Student’s t test, N = 5 animals), there 
were no differences in this purinoceptor transcript levels in 
mdx cerebellar samples (WT: 0.814 ± 0.063 P2rx7 mRNA 
level relative to Gapdh vs mdx: 0.664 ± 0.052 P2rx7 mRNA 
level relative to Gapdh; p = 0.0801; N = 11 animals). These 
Fig. 5  Dystrophin is expressed in close association with specific 
ionotropic glutamate receptor subunits. A proportion of dystrophin-
CT immunoreactive clusters are located adjacent to, or overlap with 
(arrowheads), clusters immunoreactive for the (A1–4) GluA1, (B1–4) 
GluA4, (C1–4) GluN2A, and (D1–4) GluD2 subunits. (A–D 5) show 
quantification of the relative overlap of dystrophin-CT signal with 
GluA1, GluA4, GluN2A, and GluD2, respectively, according to the 
Manders’ overlap coefficient method. The bars represent the means, 
and the errors the SEM. N = 5 animals. Scale bars: (A) 3 µm: (B 1–3) 
5 µm: (B4) 3 µm; (C) 3 µm; (D1–3) 5 µm; (D4) 3 µm
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Fig. 6  The absence of dystrophin results in changes in the expression 
of specific iGluR subunits. (A) quantification of the expression levels 
of iGluR subunit-encoding mRNA in homogenates of cerebellar ver-
mis from WT and  mdxβgeo mice relative to the Gapdh reference gene. 
The bars represent the means ± SEM. (A1–2) Unpaired Student’s t 
test: * p < 0.05; (A3–4), Mann–Whitney U test:* p < 0.05. (B) Repre-
sentative confocal micrographs of GluD2 immunofluorescence in the 
cerebellar molecular layer in tissue from (B1) WT and (B2)  mdxβgeo 
mice, processed under identical conditions. There is a noticeable 
increase in the size and density of clusters. Quantification of (B3) the 
density and (B4) size of GluD2-immunopositive clusters. Ant: inte-
rior lobe of the cerebellar vermis; Pos: posterior lobe; Floc; flocculo-
nodular lobe. Bars represent (A1–2, B) the mean, and error bars the 
SEM, and (A3) the median and error bars the interquartile range. * 
P < 0.05 unpaired Student’s t test. NS p ≥ 0.05. Scale bars: 2 µm
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Fig. 7  Dystrophin is associated with P2RX7 receptors. (A) immu-
noreactivity for P2RX7 in the cerebellar cortex is enriched in the 
molecular layer of WT mice. (B) confirmation of the specificity of the 
P2RX7 immunoreactivity, with no specific signal detected in tissue 
from P2RX7 gene-deleted mice. (C1–4) in tissue from a GFP-GFAP 
mouse, immunoreactivity for P2RX7 presents as individual clusters 
that frequently overlap (arrowheads) or appose glial processes, iden-
tified by GFP signal. (C5) quantification of the relative overlap of 
P2RX7 signal with GFP-GFAP and GFP-GFAP with P2RX7, accord-
ing to the Manders’ overlap coefficient method. The bars represent 
the means and the errors the SEM. N = 5 animals. (D1–4) dystro-
phin-CT immunoreactive clusters are located immediately adjacent 
to those immunoreactive for P2RX7 (arrowheads). This suggests 
that P2RX7 is located in glial processes that contact regions of the 
PC dendrites that express dystrophin. (D5) quantification of the rela-
tive overlap of P2RX7 signal with dystrophin-CT and dystrophin-CT 
with P2RX7, according to the Manders overlap coefficient method. 
The bars represent the means, and the errors the SEM. N = 5 animals. 
(E1–4) P2RX7 immunoreactive clusters either overlap (arrowheads) 
or are located adjacent to GluA1 immunopositive clusters. Since 
GluA1-containing receptors are expressed in both PCs and Bergman 
glia, P2RX7s could interact with both pre- and postsynaptic GluA1 
receptors. (E5) quantification of the relative overlap of P2RX7 sig-
nal with GluA1 and GluA1 with P2RX7, according to the Manders’ 
overlap coefficient method. The bars represent the means, and the 
errors the SEM. N = 5 animals. Scale bars: (a, b) 200  µm: (b, c, d 
1–2) 5 µm; (b, d 3–4) 2 µm; (c 3–4) 1 µm
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data indicate that the loss of truncated dystrophins alters the 
transcription of this key inflammatory receptor in a tissue-
specific manner.
P2RX7 activation triggers microglial activation and 
cytokine release (Barbera-Cremades et al. 2012; Di Virgilio 
et al. 1989; Steinberg and Silverstein 1987), thus, driving 
inflammatory responses. Therefore, we investigated whether 
the decreased P2rx7 mRNA observed in the brain of  mdxβgeo 
mice was indicative of a broader alteration of basal inflam-
mation. qRT-PCR analysis revealed decreased expression 
of mRNA for Cd163 (P = 0.0364, unpaired Student’s t test; 
N = 10 animals) (Fig. 9 A1), Il6 (P = 0.0248, unpaired Stu-
dent’s t test; N = 6 animals) (Fig. 9 B1), Nos2 (P = 0.0019, 
unpaired Student’s t test; N = 12 animals) (Fig. 9 C1) and 
Ptgs2 (P = 0.0032, U = 17, Mann–Whitney U test; N = 11 
animals) (Fig. 9 D1). In contrast, in the hippocampus, there 
were similar decreases in expression of Il6 (P = 0.0297, 
unpaired Student’s t test; N = 6 animals) (Fig. 9 B2) and 
Nos2 (P = 0.0051, unpaired Student’s t test; N = 8 animals) 
(Fig. 9 C2), and there were no significant changes in expres-
sion of cd163 (P = 0.4295, unpaired Student’s t test; N = 8 
animals) (Fig. 9 A2) and Ptgs2 (P = 0.2459, unpaired Stu-
dent’s t test; N = 8 animals) (Fig. 9 D2). Collectively, these 
data demonstrate that in the absence of brain dystrophins, 
there are changes in the intrinsic expression of key immune 
mediators in a region-specific manner.
Discussion
The data demonstrate that PCs target different DMD gene 
products to molecularly and functionally distinct populations 
of synapses. This suggests that an individual cell type, the 
PC, exploits different molecular variants of the dystrophin 
protein to process diverse forms of information transferred 
at excitatory and inhibitory synapses. Furthermore, the data 
reveal that in the cerebellum, truncated DMD gene prod-
ucts are located in close contact with P2RX7s, which are 
known to mediate the inflammatory component of muscle 
pathology in DMD, as well as being associated with cogni-
tive performance in dystrophic mice. However, in contrast to 
their increased expression in dystrophic muscle, expression 
of P2RX7, alongside the levels of specific pro-inflammatory 
immune mediators, is decreased in the brain of mice lacking 
all dystrophins. This suggests that the immune component 
of DMD pathology in the brain could be distinct to that in 
Fig. 8  The absence of dystrophin results in opposing changes in 
P2rx7 expression levels in muscle and brain. Quantification of 
P2RX7-encoding mRNA in (A) hind-limb tibialis anterior muscle, 
(B) cerebellum, (C) hippocampus, and (D) neocortex of WT and 
 mdxβgeo mice. Bars represent the mean and error bars the SEM; * 
p < 0.05; unpaired Student’s t test. NS not significant
▸
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other organs. This is important because the maintenance of 
homeostatic levels of pro- and anti-inflammatory mediators 
is required in facilitating a rapid, transient inflammatory 
response in the presence of invading pathogens or sterile 
trauma, and imbalances in these mediators can potentially 
render the brain unable to adequately react to such threats. 
Additionally, homeostatic levels of immune molecules are 
critical to normal development and function of neuronal 
circuits and synaptic plasticity, and therefore, alterations 
in these molecules may represent a mechanism underlying 
developmental cognitive impairment that occurs in DMD 
due to the absence of dystrophin.
The Expression of Dystrophin in the Cerebellar 
Cortex is Gene Product and Synapse Specific
The identification of the precise subcellular expression 
location of truncated dystrophins, at the protein level, 
has remained elusive. Previously published immunoblot 
data, using the same dystrophin-CT antibody used in this 
study, suggest that the predominant truncated dystrophins 
expressed in the adult rodent cerebellum are most likely 
Dp71 and Dp140 (Hendriksen et  al. 2016). Dystrophin 
immunoreactivity for putative isoforms was concentrated 
on dendritic spines on the distal dendrites of PCs through-
out the molecular layer, which is the domain of excitatory 
transmission via climbing and parallel fibre inputs. This 
builds on functional evidence using mouse models of short 
dystrophin isoforms, such as Dp71-null mice which exhibit 
altered synaptic input and plasticity at climbing fibre-PC 
synapses (Helleringer et al. 2018). These data broaden our 
understanding of the role of truncated dystrophins in cer-
ebellar function in light of the known association between 
these afferent systems and cerebellar plasticity (Kawato et al. 
2020), and the association between dystrophin deficiency 
and cerebellum-associated cognitive processes (Helleringer 
et al. 2018; Vicari et al. 2018). However, an important caveat 
is that in contrast to mice, in the human brain, DMD expres-
sion is lowest in the cerebellum (Doorenweerd et al. 2017).
The selective targeting of putative-truncated dystrophin 
to excitatory synapses appears to hold true beyond the 
cerebellum as well. Indeed, within the hippocampus, co-
immunoprecipitation analyses suggests Dp71 clustering with 
iGluR subunits and PSD-95 in rat, which is accompanied by 
altered plasticity and pre- and postsynaptic ultrastructure 
in Dp71-null mouse CA1 pyramidal neurons (Daoud et al. 
2008; Miranda et al. 2011; Miranda et al. 2009). This raises 
the question of the precise functional role of Dp71 within 
glutamatergic synapses. Since the full-length Dp427 variant 
is known to anchor α1 and α2 subunit-containing  GABAAR 
(Brunig et al. 2002; Knuesel et al. 1999), it is reasonable to 
speculate that the targeting of Dp71 to glutamatergic syn-
apses sub-serves a similar anchoring role for one or more 
specific iGluR subunits, especially given previous immu-
noprecipitation evidence of the association of Dp71 with 
PSD-95, GluA1–3, and GluN2A–B in rat hippocampal 
homogenates (Daoud et al. 2008). Indeed, the absence of 
Dp71 is reported to alter the size and distribution PSD-95 
immunoreactive clusters (Helleringer et al. 2018). Since 
findings of this study indicate that cerebellar expression of 
the GluA2–3, and GluN2A–B subunits are downregulated in 
the absence of all dystrophins, it is possible that the loss of 
Dp71 impairs the ability of PSD-95 to cluster at the synapse, 
which in turn limits its capacity to anchor specific glutamate 
receptor subunits at such locations. A possible mechanism 
for Dp71-DAPC associating with excitatory synapses could 
be via direct interaction with PSD-95. Indeed, syntrophin, a 
constituent of the DAPC, contains the PDZ domain, which 
may facilitate binding with PDZ-binding domains present 
on iGluR subunits (Traynelis 2010). Thus, the possibility 
Fig. 9  The absence of dystro-
phin results in a decrease in the 
basal expression levels of spe-
cific immune modulators in the 
cerebellum and hippocampus. 
Quantification of pro-inflamma-
tory cytokine-encoding mRNA 
within the (a) cerebellum 
and (b) the hippocampus, in 
samples from WT and  mdxβgeo 
mice. Bars represent the mean 
and error bars the SEM* (A, 
D1, 3–4) Unpaired Student’s t 
test: * p < 0.05; (D1), Mann–
Whitney U test:* p < 0.05. NS 
not significant
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exists that the DAPC is directly associated with iGluRs at 
the PSD, and that the loss of dystrophin impairs their syn-
aptic anchoring.
This role of truncated dystrophins is supported by a novel 
finding in this study that dystrophin-null but not the absence 
of the full-length variant, alters the expression of transcripts 
encoding for specific AMPA and NMDA receptor subunits. 
Interestingly, these transcriptional alterations were largely 
compensated at the protein level, and no changes were 
detected in the hippocampus. Why dystrophin would impact 
on the gene expression of these receptors in one brain region 
and not another is not immediately clear. It should be noted 
that at least ten Dp71 splice variants has been demonstrated 
in brain, including the smallest Dp40 dystrophin which has 
been detected in synapses (Austin et al. 1995). Thus, such 
differences in cellular or region influences could be linked 
to the expression of distinct variants. Unfortunately, no 
available antibodies can discriminate between such splice 
variants. Such regional differences could also be due to the 
different contributions of the cerebellum and hippocampus 
to overall brain function, as well as the functionally dis-
tinct principle cells within these structures, these being the 
GABAergic PCs of the cerebellum, and the glutamatergic 
pyramidal neurons of the hippocampus. Given the purported 
roles of dystrophin in anchoring neurotransmitter receptors 
and thereby influencing synaptic transmission, plasticity of 
dystrophin isoforms could be distinct, and according to spe-
cific functional roles within individual neural circuits, rather 
than sub-serving a common, brain-wide function. This might 
account for the diversity of neuropsychiatric symptoms aris-
ing from dystrophinopathy.
A notable discovery was the increased level of GluD2 
immunoreactivity, suggesting increased expression at the 
protein level. This is intriguing because it was the one 
receptor subunit investigated which did exhibit a consider-
able degree of colocalisation with dystrophin. Simplistically, 
this could indicate a protein–protein interaction akin to those 
occurring within the DAPC. This might provide an explana-
tion for the increased expression of GluD2 in the mdx-beta 
geo mice since this might be required to compensate for 
the total absence of all dystrophins within this model. The 
GluD2 receptor is an intriguing element of excitatory cer-
ebellar circuitry owing to both its peculiarity and pivotal role 
in facilitating cerebellar development and function. Indeed, 
several knockout studies have demonstrated that GluD2 is 
essential for circuitry and synaptic organisation and function 
in the cerebellum (Hashimoto et al., 2009; Ichikawa et al., 
2002). Furthermore, the GluD2 subunit is also crucial for 
the organisation of molecular layer synapses during post-
natal development, including PF-PC synapse morphology, 
and the expression of AMPA receptors (Kakegawa 2008; 
Uemura 2007; Watanabe and Kano 2011). This is of particu-
lar relevance to DMD because the early-juvenile onset and 
non-progressive nature of neuropsychiatric symptoms point 
to DMD-dependent cognitive deficits being of developmen-
tal origin. Such a developmental deficit may be a conse-
quence of aberrations in the neural progenitor cells develop-
ment. The expression of PC-specific Dp427 is detectable at 
12.5–13 postnatal days of mouse development (Houzelstein 
et al. 1992), and PC is reported to arise between days 11 
and 13 of mouse embryogenesis (Miale and Sidman 1961). 
Moreover, the protracted postnatal development profile of 
the cerebellum raises the question whether cerebellar dys-
functions contribute to cognitive impairment originating 
prenatally. Importantly, GluD2 immunoreactive puncta 
were larger and more abundant in  mdxβgeo mice, and previ-
ous evidence shows that Dp71-null mice exhibit impaired 
long–term potentiation. Future ultrastructural studies on the 
organisation and development of the  mdxβgeo mouse cer-
ebellum will be integral in determining whether the Dp71 
isoform contributes to postnatal cerebellar development, and 
its absence in turn is a contributor to DMD brain pathology.
Dystrophin and the Basal Immune State of the Brain
Another intriguing finding was the inter-relation between 
the expression of dystrophin, P2RX7, and cytokines within 
the cerebellum. Immunohistochemistry revealed the loca-
tion of P2RX7 at glutamatergic synapses in the cerebellar 
molecular layer, closely associated with dystrophin. Moreo-
ver, P2RX7 mRNA expression in dystrophin-null brains was 
downregulated. In muscle, dystrophinopathy coincides with 
a significant P2RX7 upregulation and altered receptor sig-
nalling in muscle cells (Young et al. 2015). Furthermore, 
dystrophic damage triggering a massive release of ATP 
coincides with the loss of DAPC, with one of its constitu-
ents, α-sarcoglycan, being an ecto-ATPase. Increased release 
combined with reduced ATPase degradation drastically 
elevate extracellular ATP (eATP) levels. Such high eATP 
activates P2RX7, which triggers chronic inflammatory and 
immune responses that exacerbate the dystrophic pathology 
(Gorecki 2019). In the brain, when activated by high eATP 
concentrations, P2RX7 also contribute to pro-inflammatory 
processes by triggering microglial activation and cytokine 
release (Iwata,  2016; Shieh et al. 2014; Solle et al. 2001), 
thus, promoting local inflammation.
The loss of dystrophin in the brain and its potential 
impact on P2RX7 expression and purinergic signalling could 
influence downstream immune and inflammatory pathways. 
The current study revealed that, in a stark contrast to its 
upregulation in dystrophic muscle, the absence of dystro-
phins results in a loco-specific decrease in brain expression 
of P2RX7. One explanation would be the different dystro-
phin isoforms being expressed in muscle and brain. The cur-
rent data, using the mdx mouse, indicate that the loss of full-
length dystrophins does not affect brain P2RX7 expression 
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nor inflammatory mediators. Thus, the loss of only long, or 
all dystrophins causes P2RX7 upregulation in muscle, the 
loss of long isoforms in the presence of truncated variants 
in brain has no effect, while the loss of all isoforms causes 
P2RX7 downregulation in the cerebellum but not in muscle 
(our data). This, therefore, suggests that it is rather not the 
difference in isoform expression but that different dystro-
phins have different functions in these two organs and, thus, 
can mediate specific aspects of DMD pathology.
Another possible explanation for the differences in in 
P2RX7 expression, in either muscle or brain, might be 
resulting not from its dysregulation due to loss of dystro-
phins but from the compensatory responses in dystrophic 
cells. P2RX7 expression allows better adaptability to unfa-
vourable metabolic conditions (Amoroso et al. 2012). Thus, 
the P2RX7 upregulation in dystrophic muscle cells might be 
an attempt to reprogram cell metabolism to meet the needs 
imposed by intrinsic metabolic abnormalities observed in 
DMD (Sharma et al. 2003) and/or adverse dystrophic mus-
cle environment (reactive oxygen species, inflammation). 
However, this compensatory P2RX7 upregulation coin-
cides with the aforementioned loss of α-sarcoglycan, which 
otherwise would eliminate excessive eATP (Sandona and 
Betto 2009). Therefore, instead of metabolic augmentation, 
high P2RX7 combined with eATP-rich environment further 
damage dystrophic muscle (Gorecki 2019). In healthy brain, 
the eATP concentration is very low (Falzoni et al. 2013). 
Therefore, brain P2RX7 activation only occurs in pathol-
ogy, where there is a rise of eATP levels (Bhattacharya and 
Biber 2016). The increased expression of P2RX7 triggers 
microglial activation and is invariably associated with neuro-
inflammation (Monif et al. 2009). Given the already perme-
able dystrophic blood brain barrier (BBB) (Lien et al. 2012), 
the inflammatory mediators released from inflamed muscle 
into the bloodstream could induce insults in brain cells and 
exacerbate abnormalities caused by the intrinsic dysregula-
tion of neuronal receptor anchorage and signalling. Indeed, 
the maintenance of homeostatic levels of inflammatory 
mediators is critical to normal development and function of 
neuronal circuits and synaptic plasticity. Therefore, it may 
represent a mechanism contributing to the developmental 
cognitive impairment in DMD. In this respect, our finding 
of altered expression of IL-6 (Fig. 9B) is directly relevant 
as both IL-6 overexpression and gene knockout have been 
associated with cognitive impairment in mice (Heyser et al. 
1997, Burton and Johnson 2012; Donegan et al. 2014). To 
counter such an inflammatory insult, dystrophic brain cells 
appear to respond with the reduced expression of P2RX7, 
which is followed by and/or coincides with the reduced 
expression of several inflammatory mediators (this work).
An additional consideration is the BBB that permeabil-
ity increases with the progressive loss of dystrophins (Lien 
et al. 2012) and can vary across different brain regions 
(Moinuddin et al. 2000). This could perhaps explain the 
P2RX7 downregulation observed in dystrophin null but not 
mdx brains and also in cerebella and hippocampi, but not 
cortical regions (this data). Furthermore, variability of brain 
inflammation due to other factors affecting the inflammatory 
mediators load and the BBB permeability could contrib-
ute to the spectrum of brain symptoms in patients with the 
same DMD mutation. This hypothesis could also explain 
why ablation of P2RX7 alleviated both muscle and brain 
phenotypes and improve certain aspects of neocortical-
dependent cognition, in the DMD mouse (Sinadinos et al. 
2015). P2RX7 ablation reduced muscle inflammation and 
also the myoblast loss, thus, improving regeneration, while 
P2RX7 absence in the brain dampened the inflammatory 
responses, thus, improving certain aspects of cognition.
Collectively, these findings suggest that different dys-
trophin isoforms are targeted to distinct neural circuits and 
may mediate specific aspects of the of DMD pathology. 
This could have important implications for the design of 
targeted future therapeutic interventions which may need to 
be isoform specific, in order to address the full spectrum of 
patient symptoms. It also raises the possibility that under-
functioning of the immune system is a component of DMD 
brain pathology, particularly those associated with neuro-
developmental processes.
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